HCA Healthcare Quarterly Earnings Beat Wall Street — But the Fine Print Tells a Different Story

There’s a certain rhythm to how HCA Healthcare reports earnings. The Nashville-based hospital giant drops its numbers, beats estimates, and the stock moves modestly one way or the other. Q2 2026 followed that pattern — mostly. Revenues climbed 8.7 percent to $20.23 billion. Diluted EPS came in at $7.62, well above where analysts had penciled it. Emergency room visits at same facilities rose 3.6 percent. On the surface, it reads like a company firing on all cylinders.

Look a little closer and the picture gets more complicated. The quarter was shaped, in large part, by a $400 million drag from what HCA calls a “payer mix shift.” What that phrase actually means is that more patients showing up at HCA hospitals don’t have insurance — or lost it.

Specifically, the company points to patients who fell off health insurance exchange plans, likely following the expiration of enhanced premium tax credits at the end of 2025. These are real people, walking through emergency room doors in Florida, Texas, and a dozen other states, receiving care that HCA will struggle to fully collect on. It’s possible that the scale of exchange coverage losses caught even HCA’s analysts off guard; the company’s estimate of that impact grew by $75 million from what it had expected just one quarter prior.

At the same time, surgical volumes declined. Same-facility inpatient surgeries fell 2.3 percent. Outpatient surgeries dropped 3.4 percent. This matters because elective and scheduled procedures tend to be among the more profitable services a hospital system provides. Fewer surgeries, more uninsured ER visits — that’s not an ideal mix, and HCA’s adjusted EBITDA margin slipping from 20.7 percent a year ago to 19.9 percent this quarter reflects exactly that tension.

What softened the blow was Florida. During Q2, the Centers for Medicare and Medicaid Services approved a directed payment program for the state, and HCA recognized roughly $1.37 billion in incremental revenues tied to it — a significant chunk of that covering periods stretching back to late 2024. Strip that out, and the quarter looks meaningfully different. It’s still unclear how investors should think about the reliability of these supplemental Medicaid payments going forward, given how dependent they are on federal approval timelines and state-level decisions.

HCA did what large, well-run companies often do when a quarter gets bumpy: it leaned on operational strength to offset structural headwinds. Expense management improved. The salaries-and-benefits ratio fell from 43.7 percent of revenues a year ago to 41.0 percent. Admissions grew. The company spent over $2 billion buying back its own shares in the quarter, signaling that management isn’t panicking. A quarterly dividend of $0.78 per share was declared, too. These are the moves of a company that believes in its own trajectory.

And yet, the full-year guidance was trimmed. HCA now expects net income between $6.3 billion and $6.7 billion for 2026, down from the $6.5 billion to $7 billion range set earlier in the year. The health insurance exchange headwind estimate for the full year was widened to between $1 billion and $1.2 billion — a notable revision from the $600 million to $900 million range from just a few months ago. These aren’t catastrophic changes, but they suggest the company is still finding its footing on exactly how many patients it will lose to the coverage gap, and for how long.

There’s a sense that what HCA is dealing with isn’t really a company-specific problem. It’s a reflection of what happens when federal health policy shifts mid-year. Hospitals across the country are navigating the same uninsured surge. HCA just happens to be large enough, and transparent enough, that its financials put a dollar figure on it. Operating 190 hospitals across 19 states and the U.K. means absorbing those policy shocks at scale — for better and for worse.

For now, the stock held up. The day after earnings, shares moved from roughly $376 to $383. Not a celebration, but not a selloff either. Investors seem to believe the operational story is intact even if the insurance coverage story remains unsettled — which, looking at everything HCA put on the table this quarter, feels about right.